ZyVersa Therapeutics’ CEO, Stephen C. Glover, Featured on Benzinga All Access Read more about ZyVersa Therapeutics’ CEO, Stephen C. Glover, Featured on Benzinga All Access
ZyVersa Therapeutics Announces Equity Research Coverage Initiated by Noble Capital Markets Read more about ZyVersa Therapeutics Announces Equity Research Coverage Initiated by Noble Capital Markets
ZyVersa Therapeutics CEO, Stephen C. Glover, Issues Letter to Shareholders Providing Outlook for 2024 Read more about ZyVersa Therapeutics CEO, Stephen C. Glover, Issues Letter to Shareholders Providing Outlook for 2024
ZyVersa Therapeutics’ CEO, Stephen C. Glover, to Participate in BIO Partnering @ JPM During “J.P. Morgan Week 2024” Read more about ZyVersa Therapeutics’ CEO, Stephen C. Glover, to Participate in BIO Partnering @ JPM During “J.P. Morgan Week 2024”
ZyVersa Therapeutics Engages CRO, George Clinical, for Phase 2a Clinical Trial for Cholesterol Efflux Mediator VAR 200 Read more about ZyVersa Therapeutics Engages CRO, George Clinical, for Phase 2a Clinical Trial for Cholesterol Efflux Mediator VAR 200
ZyVersa Therapeutics Announces Publication Demonstrating That Plasma Levels of NLRP3 Inflammasomes Correlate with Progression of Diabetic Kidney Disease in Patients with Type 2 Diabetes Read more about ZyVersa Therapeutics Announces Publication Demonstrating That Plasma Levels of NLRP3 Inflammasomes Correlate with Progression of Diabetic Kidney Disease in Patients with Type 2 Diabetes
ZyVersa Therapeutics, Inc. Announces Pricing of $5.0 Million Public Offering Read more about ZyVersa Therapeutics, Inc. Announces Pricing of $5.0 Million Public Offering
ZyVersa Therapeutics Announces Publication Showing AIM2 and NLRP3 Inflammasomes Promote Atherosclerosis in Diabetes, Supporting IC 100’s Rationale for Targeting ASC to Inhibit Multiple Inflammasome Pathways Read more about ZyVersa Therapeutics Announces Publication Showing AIM2 and NLRP3 Inflammasomes Promote Atherosclerosis in Diabetes, Supporting IC 100’s Rationale for Targeting ASC to Inhibit Multiple Inflammasome Pathways
ZyVersa Therapeutics, Inc. Announces Reverse Stock Split and Increase in Authorized Shares of Common Stock Read more about ZyVersa Therapeutics, Inc. Announces Reverse Stock Split and Increase in Authorized Shares of Common Stock
ZyVersa Therapeutics Reports Third Quarter 2023 Corporate Update and Financial Results Read more about ZyVersa Therapeutics Reports Third Quarter 2023 Corporate Update and Financial Results
